GLPG VS JNJ Stock Comparison
Performance
GLPG75/100
75/100
GLPG returned -9.92% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 74 of 100.
JNJ73/100
73/100
JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.
Analyst Price Targets
GLPG78/100
78/100
8 analysts offer 12-month price targets for GLPG. Together, they have an average target of 88.89, the most optimistic target put GLPG at 97 within 12-months and the most pessimistic has GLPG at 83.74.
JNJ63/100
63/100
23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.
Technicals
GLPG71/100
71/100
GLPG receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.
JNJ14/100
14/100
JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
GLPG10/100
10/100
GLPG has missed earnings 10 times in the last 20 quarters.
JNJ100/100
100/100
JNJ has missed earnings 0 times in the last 20 quarters.
Profit
GLPG40/100
40/100
Out of the last 20 quarters, GLPG has had 8 profitable quarters and has increased their profits year over year on 6 of them.
JNJ74/100
74/100
Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
GLPG50/100
50/100
GLPG has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
JNJ43/100
43/100
JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
Sentiment
GLPG
"Sentiment" not found for GLPG
JNJ72/100
72/100
JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.
Dividend
GLPG
"Dividend" not found for GLPG
JNJ100/100
100/100
JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Galapagos NV Summary
Nasdaq / GLPG
Healthcare
Biotechnology
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.Ã r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Johnson & Johnson Summary
New York Stock Exchange / JNJ
Healthcare
Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare GLPG to other companies in the same or a similar industry.